#United States #Los Angeles #Armata Pharmaceuticals #AP-SA02 #Staphylococcus aureus

Armata Pharmaceuticals Presents New AP-SA02 Data at ISSSI 2026

Armata Pharmaceuticals, Inc., a late-stage biotechnology firm, is poised to share significant research findings at the upcoming 20th International Symposium on Staphylococci and Staphylococcal Infections (ISSSI 2026) in Banff, Alberta. The presentation scheduled for September 21, 2026, will highlight how a defined genetic variation in AP-SA02 could enhance its capability to combat specific strains of Staphylococcus aureus, particularly those strains resistant to conventional antibiotics.

The innovation behind AP-SA02 lies in its composition—a carefully formulated bacteriophage cocktail specifically designed to treat difficult bacterial infections, especially those caused by methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) S. aureus. This presentation will delve into how genetic diversity among the components of this cocktail can significantly bolster its therapeutic effectiveness.

Key Findings

Research conducted by Armata indicates that AP-SA02 maintains a consistent and definable genetic variant profile across its clinical formulations. Genomic studies have shown that this diversity allows particular phages within the cocktail to selectively infect and replicate more efficiently on certain clinical isolates, which are crucial for rendering the product effective against a wide range of S. aureus strains.

In a comparative analysis, a phage stock that lacked this genetic diversity exhibited lower efficacy against select clinical isolates, emphasizing the importance of these variants in therapeutic success. The ability to artificially maintain this variation through controlled manufacturing processes represents an innovative aspect of AP-SA02's development, distinguishing it from other treatment modalities.

Dr. Deborah Birx, CEO of Armata Pharmaceuticals, remarked, "The controlled genomic diversity within AP-SA02 is not just an incidental characteristic; it has a fundamental role in enhancing the performance of our bacteriophage therapy. This adaptability is crucial in responding to the diverse genetic make-up of S. aureus infections across different regions and populations."

The findings discussed during the ISSSI conference will provide further mechanistic understanding and bolster confidence in advancing AP-SA02 into a Phase 3 clinical trial. The importance of these results is underscored by the positive outcomes seen in previous phases of the diSArm study, where a 100% clinical response rate was noted among patients receiving AP-SA02 therapy in conjunction with standard antibiotic treatment.

Presentation Details

• - Conference: 20th International Symposium on Staphylococci and Staphylococcal Infections (ISSSI 2026)
• - Date and Time: Monday, September 21, 2026, 5:25 PM - 5:40 PM MDT
• - Location: Banff Centre for Arts and Creativity, Banff, Alberta, Canada
• - Presenter: Renae Geier, Senior Scientist, Genomics

Armata's commitment to developing high-purity bacteriophage therapies underscores its mission to tackle antibiotic-resistant infections with innovative solutions. As they continue to navigate the complexities of bacteriophage therapy, findings from ISSSI 2026 are expected to pave the way for more effective treatments against S. aureus-related infections, further enhancing patient outcomes in critical healthcare settings.

About Armata Pharmaceuticals

Armata is dedicated to developing targeted phage therapies that address the pressing challenge of antibiotic resistance. With a growing pipeline that includes products for several significant pathogens, the company's focus on research and clinical application stands to benefit patients with complex bacterial infections. As Armata advances its initiatives—backed by regulatory designations such as Qualified Infectious Disease Product (QIDP) and Breakthrough Therapy—it remains poised to fundamentally change the landscape of infectious disease treatment.

In an era where antibiotic resistance poses a significant threat to public health, advancements in bacteriophage therapy such as those presented by Armata offer hope and innovation in treatment methodologies.